MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study
Source: View publication →
The DEFUSE 2 prospective cohort study demonstrated that acute ischemic stroke patients with an MRI target mismatch profile who achieve endovascular reperfusion have significantly higher odds of a favorable clinical outcome compared to those without a target mismatch.
Key Findings
Study Design
Study Limitations
Clinical Significance
DEFUSE 2 provided foundational proof-of-concept evidence that automated MRI-based 'target mismatch' criteria (identifying a small ischemic core with a large volume of critically hypoperfused, salvageable tissue) can successfully select acute ischemic stroke patients who are highly likely to benefit from endovascular reperfusion. This validated the tissue-based paradigm for acute stroke triage and directly set the stage for later definitive, randomized trials like DEFUSE 3 and DAWN, which utilized similar imaging criteria to extend the therapeutic window for mechanical thrombectomy up to 24 hours.
Historical Context
Prior to DEFUSE 2, the efficacy of endovascular therapy for acute ischemic stroke, particularly beyond the traditional early time windows (e.g., 3-4.5 hours for IV tPA or 6-8 hours for early endovascular devices), was uncertain. The DEFUSE 1 trial had originally proposed the target mismatch concept in patients receiving intravenous alteplase. DEFUSE 2 applied automated RAPID perfusion imaging software to an endovascular cohort treated up to 12 hours from symptom onset. It verified that imaging-selected patients derive dramatic clinical benefit from recanalization, shifting the stroke field away from strict chronological time windows toward physiological, tissue-based windows.
Guided Discussion
High-yield insights from every perspective
What is the physiological difference between the ischemic core and the ischemic penumbra, and how do diffusion-weighted imaging (DWI) and perfusion-weighted imaging (PWI) differentiate these two zones on an MRI?
Key Response
The ischemic core consists of irreversibly damaged tissue characterized by cytotoxic edema, which restricts water diffusion and appears bright on DWI. The penumbra is hypoperfused but viable tissue at risk of infarction, identified by delayed perfusion on PWI without restricted diffusion on DWI. The difference between the PWI lesion and DWI lesion defines the target mismatch.
How does the presence or absence of a target mismatch on MRI influence the decision-making process for pursuing endovascular therapy in acute ischemic stroke patients outside the standard early time window?
Key Response
Residents must understand that target mismatch helps identify patients who have salvageable brain tissue regardless of the exact time from symptom onset. Proceeding with EVT in patients without a mismatch carries a higher risk of reperfusion injury and hemorrhage without clinical benefit, whereas those with a mismatch are prime candidates for late-window EVT.
In the context of DEFUSE 2, how do specific volumetric thresholds (e.g., core volume less than 70 mL or mismatch ratio) define a target mismatch, and what are the limitations of applying these rigid thresholds in borderline clinical scenarios?
Key Response
Fellows should know that DEFUSE 2 defined target mismatch using specific criteria (e.g., mismatch ratio greater than or equal to 1.8, absolute mismatch volume greater than or equal to 15 mL, core less than 70 mL). Relying strictly on automated thresholds can be problematic in borderline cases due to imaging artifacts, the dynamic nature of stroke evolution, and individual variations in collateral circulation.
While DEFUSE 2 strongly supports EVT for target mismatch profiles, how should an attending balance advanced imaging findings with clinical gestalt, specifically in patients with severe baseline neurological deficits but equivocal mismatch profiles?
Key Response
Attendings must weigh imaging data against the patient's overall clinical picture, age, comorbidities, and baseline functional status. Over-reliance on imaging algorithms can lead to withholding potentially life-altering therapy or performing futile interventions. It highlights the art of medicine in integrating trials with personalized care.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
DEFUSE 2 was a prospective cohort study, not a randomized controlled trial. What are the inherent methodological limitations of using a cohort design to evaluate treatment response, and how might selection bias or confounding by indication have influenced the observed association between reperfusion and favorable outcomes?
Key Response
A cohort study cannot definitively prove causation because the decision to pursue endovascular therapy and the success of reperfusion are not randomized. Patients achieving reperfusion might have underlying biological differences (e.g., better collaterals, softer clots) that independently predict better outcomes, making confounding by indication a significant threat to internal validity.
As a reviewer, how would you critically evaluate the study's use of early-generation automated perfusion software (e.g., RAPID) for defining mismatch, and what concerns might arise regarding the reproducibility of these imaging parameters across different hospital settings and MRI vendors?
Key Response
Editors must scrutinize the generalizability and reproducibility of the imaging biomarker. Differences in MRI hardware, sequence parameters, and post-processing software versions can significantly alter calculated core and penumbra volumes. Ensuring that the study's automated thresholds are robust across heterogeneous real-world settings is a critical point for publication and external validity.
Based on the DEFUSE 2 findings and subsequent confirmatory randomized trials, how has the strength of recommendation for advanced imaging (CTP or MRI) changed in current AHA/ASA guidelines for selecting patients for endovascular thrombectomy in the extended 6-to-24 hour time window?
Key Response
DEFUSE 2 paved the way for phase 3 trials like DEFUSE 3 and DAWN. Current AHA/ASA guidelines give a Class I, Level of Evidence A recommendation for using CTP or DWI/PWI MRI to select patients for mechanical thrombectomy between 6 and 24 hours of last known normal. Guideline committees must utilize these foundational cohort data combined with later RCTs to establish and update the standard of care for late-window selection.
Clinical Landscape
Noteworthy Related Trials
EXTEND-IA Trial
Tested
Endovascular thrombectomy plus alteplase
Population
Ischemic stroke within 4.5 hours with large vessel occlusion and salvageable tissue on CT perfusion
Comparator
Alteplase alone
Endpoint
Reperfusion at 24 hours and early neurologic improvement
DEFUSE 3 Trial
Tested
Endovascular thrombectomy plus standard medical therapy
Population
Ischemic stroke 6 to 16 hours from onset with salvageable tissue on perfusion imaging
Comparator
Standard medical therapy alone
Endpoint
Ordinal score on the modified Rankin scale at 90 days
DAWN Trial
Tested
Endovascular thrombectomy plus standard medical therapy
Population
Ischemic stroke 6 to 24 hours from onset with clinical-core mismatch
Comparator
Standard medical therapy alone
Endpoint
Utility-weighted modified Rankin scale score at 90 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis